<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02223598</url>
  </required_header>
  <id_info>
    <org_study_id>CLC-102</org_study_id>
    <nct_id>NCT02223598</nct_id>
  </id_info>
  <brief_title>A Phase 1 Study Evaluating CB-5083 in Subjects With Lymphoid Hematological Malignancies</brief_title>
  <acronym>CLC-102</acronym>
  <official_title>A Phase 1, Dose-Escalation/Dose-Expansion Study Evaluating the Safety, Pharmacokinetics and Pharmacodynamic Effects of Orally Administered CB-5083 in Subjects With Lymphoid Hematological Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cleave Biosciences, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cleave Biosciences, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the safety, tolerability, dose limiting toxicities,
      and maximum tolerated dose of CB-5083 in subjects with lymphoid hematological malignancies.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    MTD determined
  </why_stopped>
  <start_date type="Actual">August 25, 2014</start_date>
  <completion_date type="Actual">July 26, 2017</completion_date>
  <primary_completion_date type="Actual">July 26, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To determine the dose limiting toxicities (DLTs) of oral CB-5083 in subjects with lymphoid hematological malignancies</measure>
    <time_frame>Dose Escalation Stage - the first 28 days of treatment (Cycle 1) with CB-5083</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>To determine the pharmacokinetic (PK) profile of oral CB-5083 in subjects with lymphoid hematological malignancies by measuring the AUC</measure>
    <time_frame>Dose Escalation and Dose Expansion Stages - days 1, 2, 4 and 5 of Cycle 1 and days 1 and 2 in the second 28 days (Cycle 2) of treatment with CB-5083</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>To determine the PK profile of oral CB-5083 in subjects with lymphoid hematological malignancies by measuring the Cmax</measure>
    <time_frame>Dose Escalation and Dose Expansion Stages - days 1, 2, 4 and 5 of Cycle 1 and days 1 and 2 of Cycle 2 of treatment with CB-5083</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>To determine the PK profile of oral CB-5083 in subjects with lymphoid hematological malignancies by measuring the Cmin</measure>
    <time_frame>Dose Escalation and Dose Expansion Stages - days 1, 2, 4 and 5 of Cycle 1 and days 1 and 2 of Cycle 2 of treatment with CB-5083</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>To determine the PK profile of oral CB-5083 in subjects with lymphoid hematological malignancies by measuring the Tmax</measure>
    <time_frame>Dose Escalation and Dose Expansion Stages - days 1, 2, 4 and 5 of Cycle 1 and days 1 and 2 of Cycle 2 of treatment with CB-5083</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>To determine the PK profile of oral CB-5083 in subjects with lymphoid hematological malignancies by measuring the T1/2</measure>
    <time_frame>Dose Escalation and Dose Expansion Stages - days 1, 2, 4 and 5 of Cycle 1 and days 1 and 2 of Cycle 2 of treatment with CB-5083</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>To confirm the safety and tolerability of oral CB-5083 administered to subjects with relapsed and refractory Multiple Myeloma at the maximum tolerated dose (MTD) at the end of the Dose Escalation Stage</measure>
    <time_frame>Dose Expansion Stage - from day 1 of Cycle 1 through 28 days after the patient's last cycle of treatment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>To confirm the safety and tolerability of oral CB-5083 administered to subjects with relapsed/refractory DLBCL or Waldenstrom Macroglobulinemia at the MTD</measure>
    <time_frame>Dose Expansion Stage - from day 1 of Cycle 1 through 28 days after the patient's last cycle of treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To assess the pharmacodynamic (PD) effects of CB-5083 in peripheral blood cells and cancer cells</measure>
    <time_frame>Dose Escalation and Dose Expansion Stages - days 1, 2, 4 and 5 of Cycle 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To further asses the PK profile of oral CB-5083 in subjects by measuring the AUC</measure>
    <time_frame>Dose Expansion Stages - days 1, 2, 4 and 5 of Cycle 1 and days 1 and 2 of Cycle 2 of treatment with CB-5083</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To further asses the PK profile of oral CB-5083 in subjects by measuring the Cmax</measure>
    <time_frame>Dose Expansion Stages - days 1, 2, 4 and 5 of Cycle 1 and days 1 and 2 of Cycle 2 of treatment with CB-5083</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To further asses the PK profile of oral CB-5083 in subjects by measuring the Cmin</measure>
    <time_frame>Dose Expansion Stages - days 1, 2, 4 and 5 of Cycle 1 and days 1 and 2 of Cycle 2 of treatment with CB-5083</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To further asses the PK profile of oral CB-5083 in subjects by measuring the Tmax</measure>
    <time_frame>Dose Expansion Stages - days 1, 2, 4 and 5 of Cycle 1 and days 1 and 2 of Cycle 2 of treatment with CB-5083</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To further asses the PK profile of oral CB-5083 in subjects by measuring the T1/2</measure>
    <time_frame>Dose Expansion Stages - days 1, 2, 4 and 5 of Cycle 1 and days 1 and 2 of Cycle 2 of treatment with CB-5083</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate preliminary efficacy of oral CB-5083 in subjects, using standard response criteria</measure>
    <time_frame>Dose Expansion Stages - at the end of each 28 day cycle of treatment</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>To assess the predictive value of potential baseline biomarkers for clinical trial subject enrichment strategies</measure>
    <time_frame>Dose Expansion Stages - within 28 days before day 1 of Cycle 1</time_frame>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Lymphoid Hematological Malignancies</condition>
  <condition>Relapsed and Refractory Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>Dose Escalation - CB-5083</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CB-5083 will be administered orally, 4 days on and 3 days off, for 28 day cycles, as a single agent to subjects with lymphoid hematological malignancies</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Expansion - CB-5083, Dexamethasone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CB-5083 will be administered orally, 4 days on and 3 days off, for 28 day cycles, as a single agent to subjects with relapsed and refractory multiple myeloma; in addition, subjects who develop progressive disease at the end of Cycle 1, or beyond, may receive their current dose of CB-5083 in combination with oral or IV low dose Dexamethasone (40 mg)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Expansion - CB-5083</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CB-5083 will be administered orally, daily, 4 days on and 3 days off, for 28 day cycles, as a single agent to subjects with diffuse large B-cell lymphoma (DLBCL) or Waldenstrom Macroglobulinemia, if such arm is opened, per Sponsor</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CB-5083</intervention_name>
    <arm_group_label>Dose Escalation - CB-5083</arm_group_label>
    <arm_group_label>Dose Expansion - CB-5083, Dexamethasone</arm_group_label>
    <arm_group_label>Dose Expansion - CB-5083</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <arm_group_label>Dose Expansion - CB-5083, Dexamethasone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Males and females â‰¥18 years of age at the time of signing the consent form.

          2. Dose Escalation Phase: Have a documented diagnosis of a lymphoid hematological
             malignancy as described by the 2008 World Health Organization (WHO) classification
             that requires therapy and for which there is no standard of care or standard of care
             is not expected to be effective. Subjects must not be candidates for anti-tumor
             regimens known to provide clinical benefit.

             MM Dose Expansion Cohort:

          3. Must have a documented diagnosis of relapsed and refractory multiple myeloma defined
             by the International Myeloma Working Group (IMWG) criteria.

          4. Must have measurable disease defined as:

               -  Serum M-protein â‰¥ 0.5g/dL of IgA or â‰¥ 1 g/dL of IgG, or

               -  Urine M-protein â‰¥ 200 mg/24 hr, or

               -  Involved FLC assay &gt; 10 mg/dL with abnormal FLC ratio.

          5. Must have received at least 4 prior therapies, including an alkylating agent (unless
             not clinically indicated), proteasome inhibitor, an immunomodulatory (IMiD) and CD38
             targeted therapy. At least 3 prior therapies where CD38 targeted therapies are not
             approved, not commercially accessible, contraindicated or refused by subject.

             DLBCL Dose Expansion Arm:

          6. Must have histologically confirmed DLBCL that is relapsed or refractory to previous
             therapy.

          7. Must have â‰¥1 measurable disease sites as defined by standard Lugano classification.

          8. Must have received at least 2 prior therapies, including a CD20 targeted therapy,
             alkylating agent or corticosteroid; subjects who are not eligible for high-dose
             chemotherapy and autologous stem cell transplantation (HD-ASCT) are eligible with
             exposure to at least 1 prior therapy.

             Waldstrom's Macroglobulinemia Dose Expansion Arm:

          9. Must have a confirmed diagnosis of WM as defined by the Second International Workshop,
             with a clinical indication for treatment.

         10. Must have measurable disease, defined as presence of serum immunoglobulin M (IgM) with
             a minimum IgM level of â‰¥ 2 times the upper limit of each institution's normal value is
             required.

         11. Must have relapsed/refractory disease after receiving 1 or more lines of therapy,
             including a Bruton tyrosine kinase (BTK) inhibitor (eg ibrutinib) if approved by the
             local health authority and commercially accessible.

             All Arms:

         12. Eastern Cooperative Oncology Group (ECOG) Performance Status of â‰¤2.

         13. Adequate bone marrow function without transfusion or growth factor support, defined
             as:

               -  Absolute neutrophil count â‰¥ 1,000/Î¼L;

               -  Platelet count â‰¥ 50,000/Î¼L;

               -  Hemoglobin â‰¥ 8.0 g/dL

         14. Adequate organ function defined as:

               -  Serum creatinine â‰¤ 1.5 mg/dL or creatinine clearance &gt; 45 mL/min according to
                  Cockcroftâ€‘Gault formula; (If creatinine clearance calculated from a 24-hour urine
                  sample is â‰¥45 mL/min, the subject will qualify for the study).

               -  Serum total bilirubin â‰¤ 2.0 mg/dL (34.2 Î¼mol/L); or &gt; 3.0 Ã— upper limit of normal
                  (ULN) for subjects with hereditary benign hyperbilirubinemia

               -  AST (SGOT) â‰¤ 3 Ã— the ULN;

               -  ALT (SGPT) â‰¤ 3 Ã— the ULN;

         15. Subjects who are fertile agree to use an effective barrier method of birth control
             (ie, latex condom, diaphragm, cervical cap, etc) to avoid pregnancy. Female subjects
             need a negative serum or urine pregnancy test within 7 days of study enrollment
             (applies only if subject is of childbearing potential. Nonâ€‘childbearing is defined as
             â‰¥ 1 year postmenopausal or surgically sterilized).

         16. Willing and able to provide written Informed Consent and adhere to study procedures.

        Exclusion Criteria:

          1. Subjects with leukemia are excluded, with the exception of chronic lymphocytic
             leukemia (CLL), who are allowed in the dose escalation phase. Subjects with Burkitt
             lymphoma, plasma cell leukemia, POEMS syndrome (polyneuropathy, organomegaly,
             endocrinopathy, monoclonal gammopathy, and skin changes), or amyloidosis are also
             excluded.

          2. Clinically active central nervous system (CNS) cancer involvement. Imaging to exclude
             CNS involvement not required.

          3. Previous or concomitant malignancy, except for basal-cell or squamous cell carcinoma
             of the skin or carcinoma-in-situ of the uterine cervix. Subjects with other
             malignancies are eligible if they have remained disease free for at least 2 years
             prior to study entry;

          4. Use of any anti-cancer drug therapy within 14 days prior to Baseline (within 28 days
             for monoclonal antibodies [eg anti-CD38]).

          5. Use of any investigational agent within 28 days prior to Baseline.

          6. Presence of clinically significant non-hematological toxicity of prior chemotherapy
             that has not resolved to â‰¤ Grade 1 as determined by CTCAE v 4.0, with the exception of
             alopecia and peripheral neuropathy. Note: Peripheral neuropathy &gt; Grade 2 plus pain,
             or Grade 3 or Grade 4 are excluded.

          7. Radiotherapy within 14 days prior to Baseline.

          8. Major surgery within 6 weeks prior to Baseline. The subject must have recovered from
             surgery and be without current complications of infection or dehiscence.

          9. Peripheral autologous stem cell transplant within 12 weeks prior to Baseline; prior
             allogeneic transplants within 16 weeks or chronic use of immunosuppressants.

         10. Active infection requiring systemic therapy, including known human immunodeficiency
             virus (HIV), acquired immunodeficiency syndrome-related illness, or active hepatitis B
             virus (HBV) or hepatitis C virus (HCV) infection.

         11. Major cardiac abnormalities as defined but not limited to the following: uncontrolled
             angina or unstable life-threatening arrhythmias, history of myocardial infarction
             within 12 weeks prior to Baseline, Class 3 or higher New York Heart Association (NYHA)
             congestive heart failure, or severe cardiac insufficiency, persistent (3 consecutive
             electrocardiograms (ECGs) performed â‰¥ 5 minutes apart) prolongation of the QTc
             (Fridericia) interval to &gt; 480 msec.

         12. Cerebrovascular accident, coronary/peripheral artery bypass graft surgery, transient
             ischemic attack, or pulmonary embolism within 12 weeks prior to Baseline.

         13. Major gastrointestinal (GI) disease as defined but not limited to the following:
             history of inflammatory bowel disease or other illness resulting in chronic diarrhea,
             known achlorhydria or history of GI surgery that could reduce the acidity of the
             stomach, acute pancreatitis or cholecystitis within 6 months prior to Baseline, or GI
             disease that may interfere with the absorption of orally-administered drugs.

         14. Grade 3 or 4 eye disorder at study entry, unless stable and longstanding (&gt;3 months)
             and unlikely to interfere with protocol-required ophthalmology assessments.

         15. A condition that is expected to require concomitant use of any medication listed as
             prohibited while on study.

         16. Is a pregnant or lactating female.

         17. Has any severe, acute, or chronic medical or psychiatric condition, or laboratory
             abnormality that may increase the risk associated with study participation or study
             drug administration, may interfere with the informed consent process and/or with
             compliance with the requirements of the study, or may interfere with the
             interpretation of the study results and, in the Investigator's opinion, would make the
             subject inappropriate for entry into this study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>City of Hope National Medical Center</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California, San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>RCCA MD</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hackensack University Medical Center</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Princess Margaret Cancer Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cedars Cancer Centre, McGill University Health Centre</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H4A 3J1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 15, 2014</study_first_submitted>
  <study_first_submitted_qc>August 21, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 22, 2014</study_first_posted>
  <last_update_submitted>February 23, 2018</last_update_submitted>
  <last_update_submitted_qc>February 23, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 27, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Lymphoid Hematological Malignancies</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

